EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.351
https://www.valueinhealthjournal.com/article/S1098-3015(23)03481-2/fulltext
Title :
EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03481-2&doi=10.1016/j.jval.2023.09.351
First page :
Section Title :
Open access? :
No
Section Order :
12376